BMY Quote, Financials, Valuation and Earnings

Johnson & Johnson has a net margin of 10.18% compared to Bristol-Myers Squibb's net margin of 11.99%. Bristol-Myers Squibb's return on equity of -33.18% beat Johnson & Johnson's return on equity of 20.88%.

Bristol-Myers Squibb has a consensus price target of $60.91, signalling upside risk potential of 6.25%. On the other hand Johnson & Johnson has an analysts' consensus of $172.53 which suggests that it could grow by 20.63%. Given that Johnson & Johnson has higher upside potential than Bristol-Myers Squibb, analysts believe Johnson & Johnson is more attractive than Bristol-Myers Squibb.

Bristol-Myers Squibb has a beta of 0.454, which suggesting that the stock is 54.628% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.505, suggesting its less volatile than the S&P 500 by 49.522%.

Bristol-Myers Squibb has a quarterly dividend of $0.60 per share corresponding to a yield of 4.19%. Johnson & Johnson offers a yield of 3.36% to investors and pays a quarterly dividend of $1.24 per share. Bristol-Myers Squibb pays 59.12% of its earnings as a dividend. Johnson & Johnson pays out 33.48% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Bristol-Myers Squibb quarterly revenues are $11.9B, which are smaller than Johnson & Johnson quarterly revenues of $22.5B. Bristol-Myers Squibb's net income of $1.2B is lower than Johnson & Johnson's net income of $2.7B. Notably, Bristol-Myers Squibb's price-to-earnings ratio is -- while Johnson & Johnson's PE ratio is 23.88x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bristol-Myers Squibb is 2.45x versus 4.00x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of 10.18% compared to Bristol-Myers Squibb's net margin of 8.48%. Bristol-Myers Squibb's return on equity of -33.18% beat Eli Lilly and's return on equity of 66.4%.

Bristol-Myers Squibb has a consensus price target of $60.91, signalling upside risk potential of 6.25%. On the other hand Eli Lilly and has an analysts' consensus of $984.05 which suggests that it could grow by 28.17%. Given that Eli Lilly and has higher upside potential than Bristol-Myers Squibb, analysts believe Eli Lilly and is more attractive than Bristol-Myers Squibb.

Bristol-Myers Squibb has a beta of 0.454, which suggesting that the stock is 54.628% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.409, suggesting its less volatile than the S&P 500 by 59.07%.

Bristol-Myers Squibb has a quarterly dividend of $0.60 per share corresponding to a yield of 4.19%. Eli Lilly and offers a yield of 0.68% to investors and pays a quarterly dividend of $1.30 per share. Bristol-Myers Squibb pays 59.12% of its earnings as a dividend. Eli Lilly and pays out 77.65% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Bristol-Myers Squibb quarterly revenues are $11.9B, which are larger than Eli Lilly and quarterly revenues of $11.4B. Bristol-Myers Squibb's net income of $1.2B is higher than Eli Lilly and's net income of $970.3M. Notably, Bristol-Myers Squibb's price-to-earnings ratio is -- while Eli Lilly and's PE ratio is 83.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bristol-Myers Squibb is 2.45x versus 16.99x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Merck & has a net margin of 10.18% compared to Bristol-Myers Squibb's net margin of 18.95%. Bristol-Myers Squibb's return on equity of -33.18% beat Merck &'s return on equity of 29.26%.

Bristol-Myers Squibb has a consensus price target of $60.91, signalling upside risk potential of 6.25%. On the other hand Merck & has an analysts' consensus of $128.73 which suggests that it could grow by 31.29%. Given that Merck & has higher upside potential than Bristol-Myers Squibb, analysts believe Merck & is more attractive than Bristol-Myers Squibb.

Bristol-Myers Squibb has a beta of 0.454, which suggesting that the stock is 54.628% less volatile than S&P 500. In comparison Merck & has a beta of 0.393, suggesting its less volatile than the S&P 500 by 60.746%.

Bristol-Myers Squibb has a quarterly dividend of $0.60 per share corresponding to a yield of 4.19%. Merck & offers a yield of 3.18% to investors and pays a quarterly dividend of $0.81 per share. Bristol-Myers Squibb pays 59.12% of its earnings as a dividend. Merck & pays out 2039.73% of its earnings as a dividend. Bristol-Myers Squibb's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Merck &'s is not.

Bristol-Myers Squibb quarterly revenues are $11.9B, which are smaller than Merck & quarterly revenues of $16.7B. Bristol-Myers Squibb's net income of $1.2B is lower than Merck &'s net income of $3.2B. Notably, Bristol-Myers Squibb's price-to-earnings ratio is -- while Merck &'s PE ratio is 20.56x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bristol-Myers Squibb is 2.45x versus 3.95x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of 10.18% compared to Bristol-Myers Squibb's net margin of 25.23%. Bristol-Myers Squibb's return on equity of -33.18% beat Pfizer's return on equity of 4.63%.

Bristol-Myers Squibb has a consensus price target of $60.91, signalling upside risk potential of 6.25%. On the other hand Pfizer has an analysts' consensus of $31.86 which suggests that it could grow by 20.88%. Given that Pfizer has higher upside potential than Bristol-Myers Squibb, analysts believe Pfizer is more attractive than Bristol-Myers Squibb.

Bristol-Myers Squibb has a beta of 0.454, which suggesting that the stock is 54.628% less volatile than S&P 500. In comparison Pfizer has a beta of 0.653, suggesting its less volatile than the S&P 500 by 34.739%.

Bristol-Myers Squibb has a quarterly dividend of $0.60 per share corresponding to a yield of 4.19%. Pfizer offers a yield of 6.37% to investors and pays a quarterly dividend of $0.42 per share. Bristol-Myers Squibb pays 59.12% of its earnings as a dividend. Pfizer pays out 436.39% of its earnings as a dividend. Bristol-Myers Squibb's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Pfizer's is not.

Bristol-Myers Squibb quarterly revenues are $11.9B, which are smaller than Pfizer quarterly revenues of $17.7B. Bristol-Myers Squibb's net income of $1.2B is lower than Pfizer's net income of $4.5B. Notably, Bristol-Myers Squibb's price-to-earnings ratio is -- while Pfizer's PE ratio is 35.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bristol-Myers Squibb is 2.45x versus 2.52x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.